EHA 2019 | Waldenström’s: predicting ibrutinib responses

Name: Waldenström’s: predicting ibrutinib responses
Uploaded: 2019-06-14T00:00:00.000Z
Duration: 2 min 23 s
Description: Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses data presented at EHA 2019 that investigated predictive factors for long-term response in waldenström’s macroglobulinemia treated with ibrutinib at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Steven Treon • 14 Jun 2019

EHA 2019

Rare Diseases Waldenström’s Macroglobulinemia Ibrutinib

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses data presented at EHA 2019 that investigated predictive factors for long-term response in waldenström’s macroglobulinemia treated with ibrutinib at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.